fda warning letters compounded semaglutide october 2025 Drug compounders sue over declaration ending Wegovy shortage July 29, 2024: FDA issued

When looking at long-term data from the LEADER trials, the CVOT for liraglutide, there was no difference between liraglutide and placebo regarding calcitonin levels and C-cell malignancies (83)

[UPCOMING] July 1, 2026December 31, 2027 (scheduled): Medicare GLP-1 Bridge demonstration runs nationwide

The Relationship Between GLP-1 Agonists and Arachidonic Acid The interaction between GLP-1 agonists and arachidonic acid metabolism is an emerging area of research, though there is currently no official established link recognised by regulatory bodies such as the MHRA or EMA

skin rashes or outbreaks

These are often referred to as nodules